Research ExplorerPublicationsA phase I trial investigating the Aurora B kinase inhibitor ...

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

Standard

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. / Döhner, Hartmut; Müller-Tidow, Carsten; Lübbert, Michael; Fiedler, Walter; Krämer, Alwin; Westermann, Jörg; Bug, Gesine; Schlenk, Richard F; Krug, Utz; Goeldner, Rainer-Georg; Hilbert, James; Taube, Tillmann; Ottmann, Oliver G.

In: BRIT J HAEMATOL, Vol. 185, No. 3, 05.2019, p. 583-587.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Döhner, H, Müller-Tidow, C, Lübbert, M, Fiedler, W, Krämer, A, Westermann, J, Bug, G, Schlenk, RF, Krug, U, Goeldner, R-G, Hilbert, J, Taube, T & Ottmann, OG 2019, 'A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia', BRIT J HAEMATOL, vol. 185, no. 3, pp. 583-587. https://doi.org/10.1111/bjh.15563

APA

Döhner, H., Müller-Tidow, C., Lübbert, M., Fiedler, W., Krämer, A., Westermann, J., Bug, G., Schlenk, R. F., Krug, U., Goeldner, R-G., Hilbert, J., Taube, T., & Ottmann, O. G. (2019). A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. BRIT J HAEMATOL, 185(3), 583-587. https://doi.org/10.1111/bjh.15563

Vancouver

Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J et al. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. BRIT J HAEMATOL. 2019 May;185(3):583-587. https://doi.org/10.1111/bjh.15563

Bibtex

@article{e79a9098854c4882ba33e432caa07e0d,
title = "A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia",
keywords = "Letter",
author = "Hartmut D{\"o}hner and Carsten M{\"u}ller-Tidow and Michael L{\"u}bbert and Walter Fiedler and Alwin Kr{\"a}mer and J{\"o}rg Westermann and Gesine Bug and Schlenk, {Richard F} and Utz Krug and Rainer-Georg Goeldner and James Hilbert and Tillmann Taube and Ottmann, {Oliver G}",
year = "2019",
month = may,
doi = "10.1111/bjh.15563",
language = "English",
volume = "185",
pages = "583--587",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

AU - Döhner, Hartmut

AU - Müller-Tidow, Carsten

AU - Lübbert, Michael

AU - Fiedler, Walter

AU - Krämer, Alwin

AU - Westermann, Jörg

AU - Bug, Gesine

AU - Schlenk, Richard F

AU - Krug, Utz

AU - Goeldner, Rainer-Georg

AU - Hilbert, James

AU - Taube, Tillmann

AU - Ottmann, Oliver G

PY - 2019/5

Y1 - 2019/5

KW - Letter

U2 - 10.1111/bjh.15563

DO - 10.1111/bjh.15563

M3 - SCORING: Journal article

C2 - 30450591

VL - 185

SP - 583

EP - 587

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 3

ER -